

# Case Study: Solutions for Public Health

## Auditing policy compliance for NHS England Specialised Services

NHS England Specialised Services is committed to routinely assessing that policies for using the drugs, devices and procedures they directly commission are implemented correctly.

Arden & GEM's specialist public health team, Solutions for Public Health (SPH), was commissioned by NHS England to develop a methodology for delivering the compliance audits and to undertake audits for a selection of commissioning policies that required updating.

SPH was able to select the best data sources for auditing purposes, assess whether implementation has met the commissioning criteria set out in the policy and determine whether patients have received the expected benefits from the policy interventions. The audits have also played an essential role in identifying and confirming proposed changes to the commissioning policy in response to new developments.

### The challenge

Specialised services are low volume and high cost services that are best commissioned and provided at scale, so that expertise is concentrated in a small number of specialist centres. Specialised services commissioning policies relate to a variety of interventions spanning drug treatments, medical devices and surgical procedures for a wide range of medical conditions.

For the drugs, devices and procedures they directly commission, NHS England Specialised Services is committed to initiating routine compliance testing of the implementation of adopted policies. This includes assessing:

- The number and characteristics of patients who have been treated with the intervention
- The extent to which there is equality of access to treatment throughout the NHS in England
- The extent to which numbers treated and associated costs are in line with those expected



when the policy was adopted

- Whether the use of the treatment is compliant with criteria set out in the commissioning policy
- Were the health outcomes experienced by patients similar to the outcomes expected in the policy proposal?

### Our approach

In 2023, the SPH team undertook a pilot project to develop an approach to the delivery of clinical audits. The pilot involved taking a specialised commissioning policy for a drug intervention, a medical device and a surgical procedure and identifying the routine data sources that could be used to respond to the compliance audit requirements for each type of intervention.

### Identifying the best data

A number of potential data sources are available to inform compliance audits including:

- Secondary Uses Service (SUS)
- Drugs/Devices Patient Level Contract Monitoring (DrPLCM/DePLCM)
- Clinical Utilisation Platform for Integrated Datasets (CUPID)
- Blueteq
- Clinical registries.

### Find out more...

about how we can help you improve quality and efficiency, contact NHS Arden & GEM Commissioning Support Unit:

**e:** [agem.sphsolutions@nhs.net](mailto:agem.sphsolutions@nhs.net)

**w:** [www.sph.nhs.uk](http://www.sph.nhs.uk)

Some of these data sources are held by NHS Arden & GEM, while others are held by outside agencies. One of the key tasks of the compliance audits is to identify the best data sources to address the questions that need to be answered for each audit.

The pilot assessed the strengths and weaknesses of each data source in relation to the key aims of the compliance audit including the availability of data on the demographic characteristics of the patient population. The pilot exercise resulted in the categorisation of compliance audits into three levels depending on the type of routine data available to support the audit.

### Exploring geographical variation

Following the completion of the pilot, NHS England Specialised Services introduced Systematic Component of Variation (SCV) analysis as an additional way of exploring geographical variation. SCV analysis calculates the rate for a particular intervention for England and then applies this rate to the relevant population of each NHS region to generate an estimated expected number of people that might receive the intervention. This expected number is then compared to the actual number of people receiving the intervention in each region.

### Completing compliance audits

Since the completion of the pilot, the specialised services commissioning team has tasked the SPH team with completing compliance audits on:

- Levodopa intestinal gel for Parkinson's disease
- Rituximab for neuromyelitis optica spectrum disorder (NMOSD)
- Emicizumab for haemophilia A with and without inhibitors to factor VIII.

### Outcomes

The key outcomes from the compliance audit work to date have included:

- The identification of additional sources of data to help inform specific compliance audits, for example, we were able to access a clinical database for Rituximab for the NMOSD audit.

- The added value gained from combining datasets subject to information governance requirements. For example, we have been able to improve the accuracy of ethnic group coding by matching patient records in SUS and DrPLCM/DePLCM and using data from one data source to fill gaps in the other data source.
- There is value in triangulating findings from different data sources, even if the numbers of patients do not entirely match because often the yearly trend is similar.
- The extent to which it is possible to measure compliance against inclusion and exclusion criteria stated in each commissioning policy varies according to the data sources available. Where Blueteq forms are completed (for policies developed since 2018) this is easier than for policies where Blueteq forms are not available.
- Timeframes for completion need to be flexible to take account of need to follow data request processes and information governance requirements of other agencies.
- Some commissioning policies indicate that registration of patients with a clinical registry is a specific condition of funding the intervention, but this does not appear to always be followed.

Any changes to policy or implementation arising from the audits are taken forward by the multi-agency clinical reference group responsible for the supporting commissioners to develop and implement the policy.

Quotes about the positive impact of the programme:

**"Many thanks for the work done. It is a helpful review and we will be using it to inform the discussions once they resume."**

**"I've only had a quick flick but they look great and exciting to see costs in there too. I'm very grateful to the team for their work"**

Other compliance audits are underway on spinal rods for scoliosis and catheter ablation for atrial fibrillation.

## Find out more...

about how we can help you improve quality and efficiency, contact NHS Arden & GEM Commissioning Support Unit:

**e:** [agem.sphsolutions@nhs.net](mailto:agem.sphsolutions@nhs.net)

**w:** [www.sph.nhs.uk](http://www.sph.nhs.uk)